Aa
Update on ARC 520
Arrowhead to Present at Barclays Global Healthcare Conference
PASADENA, Calif. - March 10, 2014 - Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 8:00 a.m. EST at the Loews Hotel in Miami, Florida.
A live webcast of the presentation can be accessed by visiting the News & Events section of the company's website, http://www.arrowheadresearch.com/presentations. A replay will also be archived on the website.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to ***@****
PASADENA, Calif. - March 10, 2014 - Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that President and CEO, Christopher Anzalone, Ph.D., will present at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 8:00 a.m. EST at the Loews Hotel in Miami, Florida.
A live webcast of the presentation can be accessed by visiting the News & Events section of the company's website, http://www.arrowheadresearch.com/presentations. A replay will also be archived on the website.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to ***@****
Hi pinaypie,
I am Ravi 33 years old, chronic Hep B (e-antigen negative) positive for last 5 years,
Could you please let me know that can i be a voluntary for yours trails in Arrowhead RNAi (ARC-520) treatment?
I saw many online Presentation about Arrowhead RNAi (ARC-520) it is really very grate news and this treatment looking promising also.
Please let me know whom need contact and how to approach to be voluntary for this treatment.
I am Ravi 33 years old, chronic Hep B (e-antigen negative) positive for last 5 years,
Could you please let me know that can i be a voluntary for yours trails in Arrowhead RNAi (ARC-520) treatment?
I saw many online Presentation about Arrowhead RNAi (ARC-520) it is really very grate news and this treatment looking promising also.
Please let me know whom need contact and how to approach to be voluntary for this treatment.
The phase 2 clinical trial had just started, so I don't think there will be any news.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
